logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Myasthenia Gravis Generalized

    FiltersReset Filters
    6 results

    • bkemv

      (eculizumab-aeeb)
      Amgen Inc
      Usage: BKEMV is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AchR) antibody positive.

    • rystiggo

      (ROZANOLIXIZUMAB)
      UCB, Inc.
      Usage: RYSTIGGO is indicated for treating generalized myasthenia gravis (gMG) in adult patients who test positive for either anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.

    • soliris

      (ECULIZUMAB)
      Alexion Pharmaceuticals Inc.
      Usage: SOLIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) in patients six years or older who are anti-AChR antibody positive, and neuromyelitis optica spectrum disorder (NMOSD) in anti-AQP4 antibody positive adults.

    • ultomiris

      (ravulizumab)
      Alexion Pharmaceuticals Inc.
      Usage: ULTOMIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) in patients aged one month and older, generalized myasthenia gravis (gMG) in AChR antibody-positive adults, and neuromyelitis optica spectrum disorder (NMOSD) in AQP4 antibody-positive adults.

    • vyvgart

      (EFGARTIGIMOD ALFA)
      argenx US
      Usage: VYVGART is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who test positive for anti-acetylcholine receptor (AChR) antibodies.

    • vyvgart hytrulo

      (efgartigimod alfa and hyaluronidase (human recombinant))
      argenx US
      Usage: VYVGART HYTRULO is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-AChR antibody positive and for chronic inflammatory demyelinating polyneuropathy (CIDP).